Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
probiotic + zinc L-carnosine + omeprazole
- Development stage
- Unknown
- Lead developer
- Ain Shams University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This investigational combination therapy is being evaluated by **Ain Shams University** as an adjunctive treatment for **gastroesophageal reflux disease (GERD)**. The regimen consists of a **proton pump inhibitor (PPI)**, specifically **omeprazole**, combined with **probiotic** supplementation (typically involving *Lactobacillus* and *Bifidobacterium* species) and **zinc L-carnosine**. The combination is designed to address multiple aspects of GERD pathophysiology: omeprazole reduces gastric acid secretion, zinc L-carnosine provides mucosal cytoprotection and antioxidant effects, and probiotics modulate the gut-esophageal microbiota and immune response. The therapy aims to improve clinical symptoms and reduce systemic inflammatory markers such as interleukin-6 (IL-6), interleukin-12 (IL-12), and C-reactive protein (CRP).
- Other names
- Probiotics and Zinc for GERDPPI + probiotic + zinc
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on probiotic + zinc L-carnosine + omeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on probiotic + zinc L-carnosine + omeprazole.